East Midlands Business Angels
2
1M
2
1
- Stages of investment
- Areas of investment
Summary
The main department of described VC is located in the Newark Upon Trent. The venture was found in Europe in United Kingdom.
The usual cause for the fund is to invest in rounds with 5-6 partakers. Despite the East Midlands Business Angels, startups are often financed by Catapult Ventures, University of Nottingham, Quester Capital. The meaningful sponsors for the fund in investment in the same round are University of Nottingham, Wren Capital, Origin Capital Management. In the next rounds fund is usually obtained by EASME - EU Executive Agency for SMEs.
The higher amount of exits for fund were in 2017. The high activity for fund was in 2007. Deals in the range of 1 - 5 millions dollars are the general things for fund. The fund is constantly included in less than 2 investment rounds annually.
Among the most popular fund investment industries, there are Biotechnology, Wearables. Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United Kingdom. Among the various public portfolio startups of the fund, we may underline Critical Pharmaceuticals, Monica Healthcare
Investments analytics
Analytics
- Total investments
- 2
- Lead investments
- 0
- Exits
- 1
- Investments by industry
- Biotechnology (2)
- Wearables (1)
- Health Care (1)
- Pharmaceutical (1)
- Clinical Trials (1)
- Investments by region
-
- United Kingdom (2)
- Peak activity year
- 2015
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 18
- Group Appearance index
- 1.00
- Avg. company exit year
- 12
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Critical Pharmaceuticals | 23 Feb 2007 | Biotechnology, Pharmaceutical, Clinical Trials | Early Stage Venture | 822K | England, Nottingham, United Kingdom |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.